Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

News feed

Shareholders of Ozon Pharmaceuticals approved dividends

9/25/25 OZPH

X5 has opened a distribution center for Okolo stores

9/25/25 X5

Alrosa invests ₽20 billion in Udachnaya tube

9/25/25 ALRS

Sakhalin-3 is scheduled to be launched in 2028

9/25/25 GAZP

Yandex will offer real-time AI agents to businesses

9/24/25 YDEX

Sberbank to develop drones for aerologistics

9/24/25 SBER

Hinted has opened a round of investment attraction

9/23/25 OTCI

UTair passenger traffic on airplanes in January-August decreased by 1%

9/23/25 UTAR

Expiration of the lock-up has brought down JetLend quotes

9/23/25 JETL

Tatneft reduced oil production by 1.8% in the first half of 2025%

9/23/25 TATN